Atrial natriuretic peptide in patients with diabetes mellitus type i: effects on systemic and renal hemodynamics and renal excretory function

Abstract

In the present study the effects of 1 h intravenous infusion of α-human atrial natriuretic peptide (24 ng/min/kg) on systemic and renal hemodynamics and on renal excretory function were studied in six insulin-treated and metabolically well-controlled patients with diabetes mellitus (DM) type I and in six healthy control subjects (C). Basal plasma atrial natriuretic peptide (ANP) concentration was 14.6 ± 2.0 in DM patients and 14.9 ± 1.3 pmol/L in C and rose similarly in both groups to 87.1 ± 22.1 and to 86.9 ± 11.1 pmol/L, respectively, during α-hANP infusion (P < 0.05) greater than that from 108 ± 5 to 139 ± 12 mL/min/1.73 m2in C. Effective renal plasma flow (ERPF), determined as paraaminohip-purate clearance, increased from 688 ± 51 to 821 ± 79 mL/min/1.73 m2(P